Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02129556). This is a study registration, not published results. Lead sponsor: ETOP IBCSG Partners Foundation. Recruitment status: COMPLETED. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 58 participants (ACTUAL). Conditions: Metastatic Breast Cancer. Interventions: DRUG: MK-3475. Primary outcome measures: Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab , Within the first 21 days; Objective Response Rate (ORR) , Clinical and radiological tumor assessment will be performed by CT scan or MRI at baseline, at weeks 12, 18 and 24, then every 12 weeks until progression, or 24 weeks after stop of treatment if before progression.. Brief summary: Panacea is a phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2- positive metastatic breast cancers